Annovis Bio Inc (ANVS)

Over the past six months, Annovis Bio's stock experienced several notable events, including a dilutive underwritten public offering in April 2026, which led to a stock price drop but extended the company's cash runway. Earlier in February 2026, an independent DSMB issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuation of the ongoing pivotal Phase 3 AD clinical trial without modification. In October 2025, the company reported new biomarker data from its Phase 2/3 AD trial, demonstrating potential disease-modifying activity of buntanetap. In November 2025, Annovis also reported novel biomarker data linking amyloid co-pathology in PD to accelerated cognitive decline and showed that buntanetap improved cognition in these patients. As of May 6, 2026, the stock price was $2.40 per share, representing a 51.90% increase from May 7, 2025. The 52-week high for ANVS was $5.50, occurring on November 28, 2025, and the 52-week low was $1.48 on May 12, 2025.

As a clinical-stage biotechnology company focused on developing treatments for chronic neurodegenerative diseases, Annovis Bio, Inc. does not exhibit typical demand seasonality for its products and services. The demand for its drug candidates is driven by the ongoing prevalence of diseases like Alzheimer's and Parkinson's and the progress of its clinical trials, rather than seasonal fluctuations. The company's focus is on the long-term development and eventual commercialization of its therapies to address a significant and consistent medical need.

Annovis Bio, Inc. is a late-stage clinical drug platform company in the Healthcare sector, specifically within the Biotechnology industry, dedicated to developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Their lead product candidate, buntanetap, is an investigational once-daily oral therapy designed to treat AD, PD, and other chronic neurodegenerative diseases by inhibiting the synthesis of multiple neurotoxic proteins, aiming to restore axonal and synaptic activity, reduce neuroinflammation, and protect nerve cells. The company's pipeline also includes ANVS405 for acute neurodegeneration and ANVS301 for later-stage AD and dementia.

Annovis Bio, Inc. is headquartered in Malvern, Pennsylvania, United States. The company's pivotal Phase 3 clinical trial for early Alzheimer's disease has been enrolling participants across the United States. Annovis Bio has received approval for European Union clinical trial sites for its Phase 3 study of buntanetap for the treatment of Parkinson's disease.

In the past year, Annovis Bio has maintained a reputation focused on scientific advancement and clinical progress in neurodegenerative diseases. The company has actively presented its research and findings at significant industry events, such as the AD/PD™ 2026 International Conference in March 2026 and Fierce Biotech Week 2026 in May 2026. Annovis Bio also published its Phase 2/3 Alzheimer's trial results in the peer-reviewed journal Nature NPJ Dementia in April 2026, highlighting buntanetap's safety, tolerability, and statistically significant, dose-dependent improvements in cognition in certain patient groups. Positive safety recommendations from independent Data and Safety Monitoring Boards for both Alzheimer's and Parkinson's disease trials have further supported the company's reputation for rigorous clinical development. While the dilutive equity offering in April 2026 led to a stock price decline, which could be perceived negatively by investors, the company framed it as a necessary step to fund critical Phase 3 milestones and NDA submission.

The ownership structure of Annovis Bio stock is a mix of institutional, insider, and public/individual investors. Approximately 5.98% (or 3.50% according to another source) of the company's stock is owned by Institutional Investors, 13.75% by Insiders, and 80.27% by Public Companies and Individual Investors (or 2.49% by Public Companies and Individual Investors according to another source). Another source indicates institutional ownership at 14.91% and insider ownership at 15.17%. Major institutional shareholders include Vanguard Group Inc., Marshall Wace, Llp, Two Sigma Investments, Lp, Susquehanna International Group, Llp, Jane Street Group, Llc, Geode Capital Management, Llc, Citadel Advisors Llc, BlackRock, Inc., and Northern Trust Corp. Michael B. Hoffman is noted as owning the most shares of Annovis Bio.